|
Peptides and Vaccines to inhibit Gonorrhoeae - (HJF 301-12)
Gonorrhoeae, a mucosal pathogen of the lower urogenital tract is remarkable in its capacity for antibiotic resistance. Its Multiple Transferable Resistance system (MTr) is known to enhance pathogen survival. Researchers at the Uniformed Services University (USU) and the Henry M. Jackson Foundation (HJF) have isolated the MtrE protein with possible application...
Published: 3/19/2026
|
Updated: 1/16/2026
|
Inventor(s): Ann Jerse, Amanda DeRocco
Keywords(s): Antibiotic Resistance, Antibodies, Antimicrobial, Inoculate, Neisseria gonorrhoeae, Peptide, Urogenital Tract, Vaccines
Category(s): Diagnostic, Therapeutic
|
|
Filarial Intestinal Antigens as Vaccine Candidates and Testing in Novel Animal Model of Filariasis - (HJF 378-14)
Introduction
Filariae are tissue-invasive parasitic nematodes that cause human diseases such as lymphatic filariasis, river blindness and African eyeworm; affecting over 200 million people worldwide. In addition to human disease, filarial parasites infect dogs and cats causing heartworm infections. Currently, no vaccine exists to prevent either human...
Published: 3/20/2026
|
Updated: 10/29/2025
|
Inventor(s): Edward Mitre, Christopher Morris, Sasisekhar Bennuru, Thomas Nutman
Keywords(s): B. malayi, Filarial Disease, Heartworm, Immunogen, Peptide, Vaccines
Category(s): Research Tool, Therapeutic
|
|
Novel, Cross-Sarbecovirus Neutralizing and Binding Monoclonal Antibodies (mAbs) (HJF 660-23)
The repeat emergence of SARS-CoV-2 variants of concern (VoC) with decreased susceptibility to vaccine elicited protection highlights the need to develop vaccine candidates with broad protection. Current invention identified six neutralizing antibodies with broad sarbecovirus cross-reactivity. This finding has applications towards developing next-generation...
Published: 1/27/2026
|
Updated: 5/9/2025
|
Inventor(s): Kerri Lal, Shelly Krebs, Samantha Townsley, Michael Gordon Joyce, Vincent Dussupt
Keywords(s): Antibodies, Coronavirus, Cross-Reactivity, Ferritin, Infectious Disease, Nano-particle, Neutralizing Antibodies, Respiratory, Sarbecovirus, SpFN, Spike Proteins, Vaccines, Variants, Viral
Category(s): Research Tool
|
|
Novel Vaccine Enhancers - (HJF 642-23)
Researchers at Henry M. Jackson Foundation (HJF), Uniformed Services University of the Health Sciences (USU), and Leidos Biomedical Research, Inc. (Leidos) have developed improvements to the effectiveness of mRNA vaccines. Such enhancements could reduce the number of doses needed for maximal protection, enhance vaccine durability, and reduce associated...
Published: 3/19/2026
|
Updated: 2/19/2025
|
Inventor(s): Edward Mitre, Elizabeth Graydon, Stephen Anderson
Keywords(s): mRNA, Therapeutics, Vaccines
Category(s): Therapeutic
|
|
Immunogens and Vaccine Components Against HIV - (HJF 630-22)
Henry M. Jackson Foundation (HJF) and Walter Reed Army Institute of Research (WRAIR) researchers have developed a novel vaccine strategy against HIV-1. These vaccine candidates are designed to elicit broadly neutralizing antibodies that could protect against a wide variety of HIV strains.
Applications and Advantages
Novel vaccine design approach...
Published: 2/17/2026
|
Updated: 2/12/2024
|
Inventor(s): Morgane Rolland, Eric Lewitus, Hongjun Bai, Shelly Krebs
Keywords(s): Antibodies, Assay, bnAbs, CD4, Env, HIV, Vaccines
Category(s): Therapeutic
|
|
Immunogens and Vaccine Compositions Against Flavivirus - (HJF 624-22)
HJF researchers have developed a novel recombinant flavivirus immunogen that can induce immunogenicity against multiple flaviviruses, including ZIKV (Zika) and DENV (dengue), without life-threatening antibody-dependent enhancement (ADE) responses. Mice immunized with this recombinant immunogen were protected from lethal ZIKV challenge.
Applications...
Published: 7/24/2025
|
Updated: 1/5/2024
|
Inventor(s): Shelly Krebs, Vincent Dussupt
Keywords(s): Dengue, Flavivirus, Immunogen, Vaccines, Zika
Category(s): Therapeutic, Diagnostic, Research Tool
|
|
Vaccines Against Fentanyl and Fentanyl Analogs - (HJF 561-19)
A technology related to novel fentanyl hapten compounds and their use in the preparation of vaccines against fentanyl and fentanyl analogs is available for licensing.
Applications and Advantages
Novel compounds for use as vaccines against fentanyl and analogs
High immunogenicity that generates fentanyl specific antibodies to reduce its distribution...
Published: 1/27/2026
|
Updated: 3/27/2023
|
Inventor(s): Gary Matyas, Oscar Torres, Kenner Rice, Eric Bow, Agnieszka Sulima, Arthur Jacobson
Keywords(s): Antibodies, Diagnostics, Fentanyl, Therapeutics, Vaccines
Category(s): Therapeutic
|
|
Compositions and Methods for Producing Protein Vaccines and Therapeutics - (HJF 165-07)
A technology related to compositions and methods for making protein vaccines or therapeutics is available for licensing from HJF.
This invention provides a novel composition that, when cellular extracts or whole cells are irradiated, protects cellular protein structure and function while DNA molecules are broken down. Therefore, it offers a unique...
Published: 1/13/2026
|
Updated: 3/27/2023
|
Inventor(s): Michael Daly, Elena Gaidamakova, Vera Matrosova, Rodney Levine, Nancy Wehr, Sandip Datta, Ian Myles, Cedar Fowler, Patricia Valdez
Keywords(s): Healthcare, Prevention, Therapeutics, Vaccines
Category(s): Therapeutic
|
|
Vaccines against SARS-COV-2 and other Coronaviruses - (HJF 569-20 & HJF 635-22)
Researchers at HJF and the Walter Reed Army Institute of Research (WRAIR) have developed novel vaccines comprised of fusion proteins; Ferritin nanoparticle and antigenic coronavirus peptide(s). These fusion proteins generate simultaneous protective neutralizing immune responses against coronaviruses and their variants.
Applications and Advantages
Innovation...
Published: 3/19/2026
|
Updated: 2/2/2023
|
Inventor(s): Kayvon Modjarrad, Michael Gordon Joyce
Keywords(s): Coronavirus, COVID-19, Nano-particle, SARS-CoV-2, Self-Assembly, Vaccines, Variants
Category(s): Therapeutic
|
|
Malaria Vaccine - (HJF 474-17)
A novel composition of malaria vaccine technology is available for licensing from HJF. A Phase I clinical trial has been completed and results have shown the safety and efficacy of this vaccine composition in humans.
Applications and Advantages
Novel immunogens and compositions for malaria vaccine
Significant clinical efficacy demonstrated in humans
Fully...
Published: 4/3/2026
|
Updated: 2/2/2023
|
Inventor(s): Zoltan Beck, Carl Alving, Gary Matyas, Sheetij Dutta
Keywords(s): Infectious Disease, Malaria, Prevention, Therapeutics, Vaccines
Category(s): Therapeutic
|
